T cell receptor‐engineered T cells (TCR‐T) engineered to target the new antigens associated with KRAS G12D/V can specifically recognize KRAS G12D/V mutant peptides and directly kill tumor cells by secreting cytokines, granzyme B, and perforin.[101] This approach represents a promising immunotherapeutic strategy for treating KRAS mutant solid tumors, and there are also relevant clinical trials underway (Figure 7 and Table 3). This evidence concerns the gene PRF1 and neoplasm.